TABLE 2.
Clinical trials of agents targeting TANs.
| Compound | Target | Combination partner | Tumor type | Phase | Ref. or trial no. |
|---|---|---|---|---|---|
| Agents that inhibit TAN survival | |||||
| DS-8273a | PMN-MDSCs | Monotherapy | Head and neck tumor | 3 | Dominguez et al. (2017) |
| Gemcitabine | PMN-MDSCs | Monotherapy | NSCLC | 3 | NCT03302247 |
| Fluorouracil (5-FU) | MDSC | Bevacizumab Anakinra | CRC | 2 | Isambert et al. (2018) |
| Agents that inhibit TAN recruitment | |||||
| SX-682 | CXCR2 | Pembrolizumab | Melanoma | 1 | NCT03161431 |
| Reparixin | CXCR1 | Paclitaxel | Triple-negative breast cancer | 2 | NCT02370238 |
| Agents that reprogram pre-tumor neutrophils into an antitumoral phenotype | |||||
| Fresolimumab | TGF-β | Monotherapy | Renal cell carcinoma | 1 | Lacouture et al. (2015) |
| TGF-β | Radiation therapy | Metastatic breast cancer | Completed | (Formenti et al., 2018) | |
| TGF-β | Monotherapy | High-grade gliomas | 2 | den Hollander et al. (2015) | |
| Galunisertib | TGF-β | Galunisertib | HCC | 2 | Kelley et al. (2019) |
| Sorafenib | |||||
| TGF-β | Durvalumab | Metastatic pancreatic cancer | 1 | Melisi et al. (2021) | |